When to Use Domperidone
Domperidone should NOT be used as first-line treatment for gastroparesis, but is reserved as a second-line option specifically for patients who have experienced neurologic adverse effects from metoclopramide, patients with pre-existing movement disorders like Parkinson's disease, or those who refuse metoclopramide due to concerns about its side effects 1.
Primary Indication: Gastroparesis (Second-Line Only)
The 2025 AGA guidelines explicitly recommend against domperidone as first-line therapy for gastroparesis (conditional recommendation, very low quality evidence) 1. However, through shared decision-making, domperidone becomes a reasonable option when:
Specific Clinical Scenarios for Use:
- Metoclopramide intolerance: Patients who developed extrapyramidal symptoms, tardive dyskinesia, or other neurologic adverse effects from metoclopramide 1
- Parkinson's disease patients: Those with pre-existing movement disorders where metoclopramide would be contraindicated 1
- Patient refusal of metoclopramide: When patients decline metoclopramide specifically due to concerns about neurologic side effects 1
- Symptom profile: Patients who place high value on potential improvement in nausea, vomiting, and early satiety 1
Critical Pre-Treatment Requirements
Before initiating domperidone, you must obtain 1:
- Baseline ECG to measure QTc interval
- Serum potassium and magnesium levels
- FDA expanded access IND application (in the United States - domperidone is not FDA-approved for human use) 1
Important Caveat:
The current supplier for domperidone under FDA IND in the United States is exiting the business and will no longer supply the medication 1. This significantly limits availability in the U.S.
Dosing and Monitoring Protocol
Standard dosing: 10 mg three to four times daily (30-40 mg/day total) 2
Monitoring schedule 1:
- Assess efficacy at 4-8 weeks to determine continuation
- Monitor serum potassium, magnesium, and ECG QTc interval throughout treatment
- Long-term data shows patients can safely continue for years (mean 7.6 years in one study) with careful monitoring 2
Absolute Contraindications
Do not use domperidone in patients with 3:
- Pre-existing QT prolongation or Long QT Syndrome (LQTS)
- Concurrent use of CYP3A4 inhibitors
- Electrolyte abnormalities (hypokalemia, hypomagnesemia)
- Other risk factors for QT prolongation
- History of ventricular arrhythmias
- Prolactinoma
- Pregnancy or breastfeeding (unless specifically for lactation induction with careful monitoring)
Mechanism and Expected Benefits
Domperidone works as a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic effects 4, 5. Unlike metoclopramide, it minimally crosses the blood-brain barrier, explaining its lower risk of neurologic side effects 4.
Expected symptom improvement 2:
- Nausea (primary benefit)
- Postprandial fullness
- Loss of appetite
- Vomiting
In long-term studies, 36% of patients continued treatment with reports of being "moderately better" (CPGAS score 2.3/3.0) 2.
Common Pitfalls to Avoid
- Using as first-line therapy: Metoclopramide or erythromycin should be tried first 1
- Ignoring cardiac monitoring: QTc prolongation is a real risk - 9.5% experienced meaningful prolongation in one study at 120 mg/day 6
- Exceeding recommended doses: While doses up to 120 mg/day have been studied, standard dosing is 30-40 mg/day 2
- Forgetting electrolyte monitoring: Hypokalemia and hypomagnesemia increase arrhythmia risk 1
- Prescribing without IND approval (in U.S.): This is required for legal use 1
Side Effects Leading to Discontinuation
In long-term studies, 100 of 529 patients (19%) stopped domperidone due to side effects 2:
- Palpitations (most common)
- Prolonged QTc
- Chest pain
- Diarrhea
- Headache
- Dizziness
- Lactation/galactorrhea
Alternative Context: Parkinson's Disease
Domperidone is used off-label in Parkinson's disease for dopaminergic-induced nausea 7. However, 95% of prescriptions in France violated EMA guidelines (which restrict use to ≤60 years, ≤30 mg/day, ≤7 days) 7, highlighting the tension between regulatory restrictions and clinical need in this population.
Bottom Line Algorithm
- First-line: Use metoclopramide or erythromycin for gastroparesis 1
- If metoclopramide fails or causes neurologic side effects: Consider domperidone
- Screen for contraindications: Check ECG, electrolytes, medication interactions
- Obtain FDA IND approval (if in U.S.)
- Start 10 mg TID-QID
- Reassess at 4-8 weeks with repeat ECG and electrolytes
- Continue only if beneficial with ongoing cardiac monitoring